Core Viewpoint - The clean energy sector demonstrated resilience in 2025 despite challenges from fossil fuel prioritization, with expectations for continued growth in 2026 driven by ongoing transformations in energy and technology [1][2]. Industry Summary - The S&P Global Clean Energy Transition index increased by 46% in 2025, significantly outperforming the broader S&P 500, which rose by 16% [1]. - The clean energy transformation is anticipated to reshape markets such as infrastructure and transportation, leading to new growth opportunities for companies involved in this transition [3]. Company Insights - MYR Group (Ticker: MYRG) reported a 53% return in 2025 and is viewed as a strategic investment in the electrical infrastructure sector, expected to benefit from rising demand due to the AI boom [4][5]. - Recursion Pharmaceuticals (Ticker: RXRX) experienced a -44% return in 2025 but is recognized for its commitment to sustainability. The company is expected to leverage AI advancements in biotechnology and pharmaceuticals, making it a stock to watch [6].

Core Insights - Major players in the healthcare sector are increasing their capital return commitments to shareholders, leading to higher dividends and evolving capital return strategies [3] Company Summaries - **Stryker (NYSE: SYK)**: - Market capitalization is approximately $135 billion, making it a significant player in healthcare equipment and supplies [4] - Despite steady revenue growth and margins, Stryker's total return in 2025 is around -1% [4] - Recently announced a 4.8% increase in quarterly dividend to 88 cents per share, payable on January 30, 2026 [5] - Analysts have a bullish outlook with a consensus price target of just under $432, indicating a potential upside of 22% [6] - **Amgen (NASDAQ: AMGN)**: - Market capitalization is about $171 billion, ranking among the top ten in biotechnology and pharmaceuticals [6] - The stock has performed well in 2025 with a total return of approximately 26% [6] - Latest earnings report showed strong performance with 16 drugs achieving double-digit growth rates, and the largest revenue driver, Prolia, grew by 9% [6] - Amgen now offers a leading dividend yield of 3.2%, one of the few large-cap healthcare stocks above 3% [7] - **Eli Lilly**: - Along with Stryker and Amgen, Eli Lilly has also raised its dividends, indicating a trend of increased capital returns to shareholders [7] - Analysts maintain a positive outlook for Eli Lilly, with implied upside potential following Stryker and Amgen [7]

Core Viewpoint - COSCIENS Biopharma Inc. has approved a plan to voluntarily delist from Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX) to focus resources on core business needs and enhance operational efficiency [1][8]. Financial Highlights - For Q2 2025, total revenue was $2.7 million, a 17% increase compared to $2.3 million in Q2 2024 [17]. - Gross profit for Q2 2025 increased by 19% compared to the same period in 2024 [7]. - Operating expenses decreased by 28% compared to Q2 2024, totaling $3.3 million [18]. Strategic and Operational Updates - The company underwent a leadership change with a new CEO and a reconstituted Board of Directors, focusing on operational discipline and cost control [4][3]. - A zero-based budgeting initiative was launched, resulting in a 27% reduction in headcount to align costs with strategic priorities [6]. - The company is focusing on optimizing its revenue-generating base business and exploring new business development opportunities [5]. Nasdaq Delisting - The decision to delist from Nasdaq was driven by increasing costs associated with maintaining dual listings and a deteriorating cost-benefit ratio [8]. - The company plans to file a Form 25 with the SEC around August 25, 2025, with the delisting expected to be effective on or about September 5, 2025 [9][10]. Product and Market Development - The company is exploring new category expansion opportunities for its active ingredients, including beta glucan and avenanthramides [14]. - Despite challenges in the Macrilen product line, the company is assessing future development options and has ongoing clinical studies for its inflammation-related program [14]. Cash Position - As of June 30, 2025, the company had $9.3 million in cash and cash equivalents [15]. Overall Performance - For the six-month period ended June 30, 2025, the company reported a consolidated net loss of $6.0 million, compared to a loss of $2.8 million for the same period in 2024 [19]. - Total revenue for the six-month period was $4.2 million, a slight decrease from $4.4 million in the prior year [20].